Immuneering Income Statement (2020-2026) | IMRX

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.66M0.48M0.19M0.18M0.09M0.04M455.00
Gross Profit (Quarter)
0.34M0.26M-0.02M0.09M0.05M0.02M455.00
Operating items
Amortization - Intangibles (Quarter)
0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Research & Development (Quarter)
6.99M6.21M7.95M9.06M7.98M9.36M9.87M10.21M9.45M10.05M11.91M11.20M10.65M11.25M14.86M11.47M10.45M10.87M9.25M10.65M
Selling, General & Administrative (Quarter)
1.34M2.60M3.15M3.95M3.70M3.84M4.11M4.46M4.04M3.87M4.38M4.12M4.25M4.01M3.69M4.01M4.30M4.51M4.49M4.68M
Other Operating Expenses (Quarter)
0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Operating Expenses (Quarter)
8.33M8.81M11.10M13.02M11.69M13.21M13.99M14.68M13.50M13.93M16.30M15.33M14.91M15.27M18.56M15.48M14.76M15.38M13.75M15.34M
Operating Income (Quarter)
-7.99M-8.54M-11.12M-12.93M-11.65M-13.19M-13.99M-14.68M-13.50M-13.93M-16.30M-15.33M-14.91M-15.27M-18.56M-15.48M-14.76M-15.38M-13.75M-15.34M
EBIT (Quarter)
-7.99M-8.54M-11.12M-12.93M-11.65M-13.19M-13.99M-14.68M-13.50M-13.93M-16.30M-15.33M-14.91M-15.27M-18.56M-15.48M-14.76M-15.38M-13.75M-15.34M
Non-operating items
Non Operating Investment Income (Quarter)
-0.00M-0.04M-0.12M-0.01M0.04M0.11M
Interest & Investment Income (Quarter)
0.00M0.02M0.14M0.13M0.14M0.22M0.52M0.83M1.17M0.86M0.75M0.80M0.83M0.55M0.42M0.44M0.32M0.42M1.86M1.36M
Other Non Operating Income (Quarter)
-0.01M-0.12M-0.10M-0.02M0.12M0.22M0.24M0.15M0.48M0.46M0.21M0.01M0.13M0.09M0.31M0.51M
Net income details
EBT (Quarter)
-19.54M-64.86M-11.00M-18.08M-19.38M-38.85M-13.60M-14.06M-34.34M-25.99M-15.74M-14.71M-20.42M-20.88M-18.33M-15.23M-20.04M-44.50M-12.08M-32.05M
Profit After Tax (Quarter)
-7.99M-8.54M-10.78M-12.90M-0.01M-12.84M37.29M0.03M-12.19M-12.60M38.38M-14.31M-14.08M-14.60M-18.05M-15.05M-14.43M-14.96M-11.50M-13.78M
Income from Non-Controlling Interests (Quarter)
-0.12M-0.01M0.04M0.11M0.03M-0.00M0.01M-0.01M-306.000.00M0.01M-0.01M0.08M-0.32M
Income from Continuing Operations (Quarter)
-19.54M-64.86M-11.00M-18.08M-19.38M-38.85M-13.60M-14.06M-34.34M-25.99M-15.74M-14.71M-20.42M-20.88M-18.33M-15.23M-20.04M-44.50M-12.08M-32.05M
Consolidated Net Income (Quarter)
-19.54M-64.86M-11.00M-18.08M-19.38M-38.85M-13.60M-14.06M-34.34M-25.99M-15.74M-14.71M-20.42M-20.88M-18.33M-15.23M-20.04M-44.50M-12.08M-32.05M
Income towards Parent Company (Quarter)
-19.54M-64.86M-11.00M-18.08M-19.38M-38.85M-13.60M-14.06M-34.34M-25.99M-15.74M-14.71M-20.42M-20.88M-18.33M-15.23M-20.04M-44.50M-12.08M-32.05M
Net Income towards Common Stockholders (Quarter)
-19.54M-64.86M-11.00M-18.08M-19.38M-38.85M-13.60M-14.06M-34.34M-25.99M-15.74M-14.71M-20.42M-20.88M-18.33M-15.23M-20.04M-44.50M-12.08M-32.05M
Additional items
EPS (Basic) (Quarter)
-3.94-3.55-0.81-0.69-0.73-1.47-0.52-0.53-1.20-0.89-0.55-0.50-0.69-0.70-0.61-0.43-0.56-1.12-0.27-0.50
EPS (Diluted) (Quarter)
-3.94-3.55-0.81-0.69-0.73-1.47-0.52-0.53-1.20-0.89-0.55-0.50-0.69-0.70-0.61-0.43-0.56-1.12-0.27-0.50
Shares Outstanding (Quarter)
4.95M18.29M13.61M26.36M26.39M26.39M26.39M26.44M28.65M29.27M28.42M29.37M29.65M29.84M29.98M35.53M35.99M39.67M44.01M64.66M
Shares Outstanding (Diluted) (Quarter)
4.95M18.29M13.61M26.36M26.39M26.39M26.39M26.44M28.65M29.27M28.42M29.37M29.65M29.84M29.98M35.53M35.99M39.67M44.01M64.66M
EBITDA (Quarter)
-7.99M-8.54M-11.12M-12.93M-11.65M-13.19M-13.99M-14.68M-13.50M-13.93M-16.30M-15.33M-14.91M-15.27M-18.56M-15.48M-14.76M-15.38M-13.75M-15.34M
Interest Expenses (Quarter)
11.55M56.34M0.03M5.29M7.88M25.89M0.13M0.22M22.00M12.92M0.19M0.19M6.33M6.15M0.18M0.18M5.60M29.54M0.19M18.08M